Navigation Links
Metabolex Appoints Raymond Urbanski M.D., Ph.D. to Position of Chief Medical Officer
Date:10/20/2011

e is being combined with the xanthine oxidase inhibitors allopurinol and febuxostat (Uloric™, Takeda Pharmaceutical Company Limited). The study using arhalofenate (400 and 600 mg) in combination with allopurinol is a randomized double-blind placebo-controlled study in patients who are refractory to allopurinol (do not reach their serum uric acid goal of <6 mg/dL). The primary endpoint is the percentage of patients that reach goal.  

The Phase 2b combination study with febuxostat is an open-label study in which 400 and 600 mg doses of arhalofenate are added on to febuxostat (80 mg) to assess how low uric acid levels can be driven.  This study is also fully enrolled. Data from all three Phase 2b studies will be available in the second quarter of 2012.  

"I am very excited about joining Metabolex and leading the arhalofenate gout program," said Ray Urbanski. "The Phase 2 program that is in place reflects the potential that arhalofenate has of achieving a broad label for the treatment of hyperuricemia and gout including first-line use and, for patients not reaching treatment goals, in combination with allopurinol or febuxostat, as well as addressing some common gout co-morbidities. Arhalofenate is a potential best-in-class drug that is highly de-risked and has tremendous commercial potential."  

Arhalofenate has previously completed eight Phase 1 and four Phase 2 studies in patients with Type 2 diabetes which demonstrate that it has excellent safety and tolerability in more than 550 patients for up to 6 months of treatment. The drug has completed all preclinical safety studies including the carcinogenicity studies and is therefore highly de-risked with regard to both preclinical and clinical safety.  

The clinical data from the diabetes trials showed that arhalofenate exhibited robust, dose-dependent reductions in serum uric acid.  These reductions were fully retained in patients with mild to moderate re
'/>"/>

SOURCE Metabolex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Metabolex Initiates Phase 2 Trial of Arhalofenate
2. Metabolex Announces Election of Kurt von Emster to Board of Directors
3. Metabolex Announces Positive Results From Phase 1a Clinical Trial of MBX-2982
4. Two Metabolex Projects Recognized in Windhovers Top 10 Lists for Partnering Opportunities
5. Amgen Appoints Anthony (Tony) Hooper Executive Vice President Global Commercial Operations
6. Kessler Foundation Appoints New Director of Human Performance and Engineering Laboratory
7. China Botanic Appoints Zack Zibing Pan as an Independent Director and Chairman of its Audit Committee
8. Immune Design Corp. Appoints Guy F. Cipriani as Chief Business Officer
9. Amgen Appoints Robert A. Bradway to the Companys Board of Directors
10. PrimeraDx Appoints Jeff Liter as VP of Corporate Development
11. Oncobiologics Appoints Scott Canute, Former President of Eli Lilly and Genzyme, to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... processes prefer to settle into equilibriuma state of ... the realm of non-equilibrium conditions where new possibilities ... and phases, such as temperature fluctuations, freezing and ... regulate their body temperature, airplanes to fly, and ... , But even though these conditions exist naturally ...
(Date:7/24/2014)... N.J. , July 24, 2014  CorMedix ... on developing and commercializing therapeutic products for the ... today announces receipt of notice on July 18, ... the NYSE-MKT has accepted the CorMedix plan to ... NYSE-MKT. As a result, the NYSE-MKT is continuing ...
(Date:7/24/2014)... 1000 balances – 4 steps – One Recommendation: the ... expertly narrows down the mass of product choices to ... , First, select the working environment, then enter ... and define the accuracy – it’s really that simple. ... list to models that fit best with the customer’s ...
(Date:7/24/2014)... As part of the long-term strategic approach, ... region during 2014 with potential global expansion. , "We ... DZS to manage our clinical trials globally and in ... R&D and President of SBI pharmaceuticals MENA, Dr. Riyadh ... a focus on utilizing eClinical software and flexible team ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2
... Oct. 23 BioWisdom Ltd (BioWisdom),the market ... industry, today announces the release of OmniViz,Visualization ... are increasingly being used in competitive business ... business decisions.,OmniViz Visualization Software can turn the ...
... Israel and JERSEY CITY, New Jersey, October 23, ... in,the development of microRNA-based diagnostics and therapeutics, today,announced ... Annual,Meeting on "Molecular Markers in Cancer". The event ... in Hollywood, Florida., The poster presentation, titled ...
... FRANCISCO, Calif., Oct. 23 Poniard,Pharmaceuticals, Inc. (Nasdaq: ... today announced that it will hold a conference ... provide a corporate update,including an update on the ... candidate., Jerry McMahon, Ph.D., chairman and chief ...
Cached Biology Technology:Rosetta Genomics to Present at the Upcoming EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer" 2Rosetta Genomics to Present at the Upcoming EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer" 3Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30 2
(Date:7/24/2014)... wildlife loss leads to conflict among people around the ... Society (WCS) Health & Ecosystems: Analysis of Linkages (HEAL) ... approach to tackle global biodiversity decline. , The harvest ... world,s people and provides protein for more than a ... no surprise that today,s unprecedented loss of wildlife, is ...
(Date:7/24/2014)... Bushmeat, the use of native animal species for food ... be a significant factor in the decline of many ... new study indicates that more than half of the ... raptors and hornbills., "By surveying not only the meat ... being eaten inside the forest by hunters and brought ...
(Date:7/24/2014)... Angeles, where electric cars ply silent freeways, solar panels ... beneath the earth, from howling winds and from the ... that it is technically and economically feasible to convert ... renewable energy. Published in Energy , the plan ... energy supply in California that could create tens of ...
Breaking Biology News(10 mins):New study draws links between wildlife loss and social conflicts 2Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4
... French . Some of the human X chromosome ... Africa, according to an international team of researchers led by ... of Montreal and the CHU Sainte-Justine Research Center. The research ... and Evolution. "This confirms recent findings suggesting ...
... July 18, 2011 Researchers at UT Southwestern Medical ... involved in the formation of colon cancer, far more ... study, published in the July 2011 Cancer Research (Priority ... cancer treatments targeting multiple genes and pathways simultaneously. Current ...
... YORK, July 16, 2011 Experts from the Center ... Center will present new research at the 2011 Alzheimer,s ... in Paris, France from July 16 21. ... impairment in retired football players, with Stella Karantzoulis, PhD, ...
Cached Biology News:Genetic research confirms that non-Africans are part Neanderthal 2NYU Langone Medical Center's tip sheet to the 2011 Alzheimer's Association International Conference 2NYU Langone Medical Center's tip sheet to the 2011 Alzheimer's Association International Conference 3NYU Langone Medical Center's tip sheet to the 2011 Alzheimer's Association International Conference 4NYU Langone Medical Center's tip sheet to the 2011 Alzheimer's Association International Conference 5NYU Langone Medical Center's tip sheet to the 2011 Alzheimer's Association International Conference 6
For removal of the zona pellucida. Sterile, Mouse Embryo tested...
... The LXQ linear ion trap mass spectrometer ... analytical laboratory., The LXQ linear ion trap ... and proteomic applications, delivering the fast cycle ... linear ion trap at an attractive price. ...
... scientists who do not have access to microarray ... their biological samples tested for the concentration of ... 1-2-3 Chose the analytes you wish ... S&S antibody menu. Send your samples to ...
... Persistent Analysis Environment 2) Dot plot, ... 3) Software Compensation 4) Cell Cycle ... Platform 7) Intelligent batch generation of graphs ... 9) Single drag-and-drop operations to perform complex ...
Biology Products: